1
|
Amirdhanayagam J, Guleria M, Sharma R, Kumar N, Mukherjee A, Das T. Formulation of patient dose of [ 177Lu]Lu-Trastuzumab using in-house developed freeze-dried kit: A path forward for clinical translation. J Labelled Comp Radiopharm 2024; 67:131-144. [PMID: 38342496 DOI: 10.1002/jlcr.4086] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2023] [Revised: 01/15/2024] [Accepted: 01/16/2024] [Indexed: 02/13/2024]
Abstract
Trastuzumab is a US-FDA-approved humanized monoclonal antibody used for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer. The aim of the present work is to optimize a freeze-dried formulation of DOTA-Trastuzumab conjugate for the preparation of patient doses of [177Lu]Lu-Trastuzumab for radioimmunotherapy of breast cancer. The formulation of [177Lu]Lu-Trastuzumab usually takes a long time, and thus, such a process is not suitable for the routine preparation of this agent in hospital radiopharmacies. To circumvent this, a pre-synthesized DOTA-Trastuzumab conjugate as a freeze-dried formulation is proposed. In the present work, DOTA-Trastuzumab conjugate was subjected to a freeze-drying process after the addition of optimized amounts of radioprotectant and cryoprotectant. [177Lu]Lu-DOTA-Trastuzumab was prepared by incubating the lyophilized powder of the kit vial with medium-specific activity 177LuCl3. The final radiochemical purity of [177Lu]Lu-DOTA-Trastuzumab, prepared using freeze-dried kit, was determined to be >95%. To ascertain the reproducibility of the procedure, six consecutive batches of the freeze-dried formulation were prepared, radiolabeled, and evaluated by carrying out both in vitro and ex vivo studies. The consistency of the results of all the six consecutive batches confirmed the robustness and utility of the in-house optimized freeze-dried formulation for the preparation of patient doses of [177Lu]Lu-Trastuzumab at hospital radiopharmacies.
Collapse
Affiliation(s)
| | - Mohini Guleria
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, India
- Homi Bhabha National Institute, Mumbai, India
| | - Rohit Sharma
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, India
- Homi Bhabha National Institute, Mumbai, India
| | - Naveen Kumar
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, India
- Homi Bhabha National Institute, Mumbai, India
| | - Archana Mukherjee
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, India
- Homi Bhabha National Institute, Mumbai, India
| | - Tapas Das
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, India
- Homi Bhabha National Institute, Mumbai, India
| |
Collapse
|
2
|
Kumar N, Guleria M, Shelar S, Amirdhanayagam J, Das T. Copper metal insertion in porphyrin core compromises the photocytotoxicity of free base porphyrin: Revelation during synthesis of natCu/[64Cu]Cu-porphyrin complex. J Photochem Photobiol A Chem 2023. [DOI: 10.1016/j.jphotochem.2023.114754] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/09/2023]
|
3
|
Guleria M, Suman SK, Kumar N, Sharma AK, Amirdhanayagam J, Sarma HD, Satpati D, Das T. Evaluation of the effect of a cell penetrating peptide (TAT) towards tailoring the targeting efficacy and tumor uptake of porphyrin. RSC Med Chem 2022; 13:1378-1390. [PMID: 36439980 PMCID: PMC9667781 DOI: 10.1039/d2md00097k] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2022] [Accepted: 08/08/2022] [Indexed: 08/13/2023] Open
Abstract
Cell penetrating peptides (CPPs) are known to possess a unique capacity to penetrate biological membranes and translocate various molecules into the cells. Therefore, porphyrin-CPP conjugates could be envisaged to boost the intracellular delivery of porphyrins thereby providing an improved tool for the development of agents for multi-modal applications for cancer management. Working in this direction, an unsymmetrically substituted porphyrin derivative was conjugated with a transactivating transcriptional activator peptide (TAT) and various in vitro and in vivo studies were carried out in order to study the effect of adding a CPP to the porphyrin derivative. MTT assay revealed the preferential light dependent toxicity of the porphyrin derivative which was further enhanced upon peptide conjugation. Fluorescence and flow cytometry studies revealed the relatively higher cellular internalization of the porphyrin-TAT conjugate in comparison with the porphyrin derivative. The elevated light dependent cell toxicity of the porphyrin-TAT conjugate along with its capability of generating cytotoxic singlet oxygen indicated the advantages of using the porphyrin-TAT conjugate for PDT applications. Also, porphyrin and the porphyrin-peptide conjugate were radiolabelled with 68Ga to investigate their possible potential as PET agents. In vivo biodistribution studies revealed a higher tumor uptake for the 68Ga-porphyrin-TAT conjugate (6.32 ± 1.24% IA per g) than for 68Ga-porphyrin (2.45 ± 0.88% IA per g) at 60 min post-administration. However, the observation of a higher non-target retention of the radiolabelled agents during in vivo studies might pose a limitation on their possible application in PET imaging.
Collapse
Affiliation(s)
- Mohini Guleria
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre Trombay Mumbai - 400085 India 91 22 2550 5151 91 22 2559 0613
- Homi Bhabha National Institute Anushaktinagar Mumbai - 400094 India
| | - Shishu K Suman
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre Trombay Mumbai - 400085 India 91 22 2550 5151 91 22 2559 0613
- Homi Bhabha National Institute Anushaktinagar Mumbai - 400094 India
| | - Naveen Kumar
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre Trombay Mumbai - 400085 India 91 22 2550 5151 91 22 2559 0613
- Homi Bhabha National Institute Anushaktinagar Mumbai - 400094 India
| | - Amit K Sharma
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre Trombay Mumbai - 400085 India 91 22 2550 5151 91 22 2559 0613
- Homi Bhabha National Institute Anushaktinagar Mumbai - 400094 India
| | - Jeyachitra Amirdhanayagam
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre Trombay Mumbai - 400085 India 91 22 2550 5151 91 22 2559 0613
| | - Haladhar D Sarma
- Radiation Biology and Health Sciences Division, Bhabha Atomic Research Centre Trombay Mumbai - 400085 India
| | - Drishty Satpati
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre Trombay Mumbai - 400085 India 91 22 2550 5151 91 22 2559 0613
- Homi Bhabha National Institute Anushaktinagar Mumbai - 400094 India
| | - Tapas Das
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre Trombay Mumbai - 400085 India 91 22 2550 5151 91 22 2559 0613
- Homi Bhabha National Institute Anushaktinagar Mumbai - 400094 India
| |
Collapse
|
4
|
Kumar N, Guleria M, Chakraborty A, Amirdhanayagam J, Bannore TU, Damle A, Sarma HD, Das T. Synthesis and evaluation of [
177
Lu]Lu‐labeled porphyrin loaded PAMAM dendrimer: Impact on tumor uptake and pharmacokinetics. Drug Dev Res 2022; 83:1777-1790. [DOI: 10.1002/ddr.21996] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2022] [Revised: 08/14/2022] [Accepted: 08/26/2022] [Indexed: 11/11/2022]
Affiliation(s)
- Naveen Kumar
- Radiopharmaceuticals Division Bhabha Atomic Research Centre Mumbai Maharashtra India
- Department of Chemical Sciences Homi Bhabha National Institute Mumbai Maharashtra India
| | - Mohini Guleria
- Radiopharmaceuticals Division Bhabha Atomic Research Centre Mumbai Maharashtra India
- Department of Chemical Sciences Homi Bhabha National Institute Mumbai Maharashtra India
| | - Avik Chakraborty
- Radiation Medicine Centre Bhabha Atomic Research Centre Mumbai Maharashtra India
| | | | | | - Archana Damle
- Radiation Medicine Centre Bhabha Atomic Research Centre Mumbai Maharashtra India
| | - Haladhar D. Sarma
- Radiation Biology and Health Sciences Division Bhabha Atomic Research Centre Mumbai Maharashtra India
| | - Tapas Das
- Radiopharmaceuticals Division Bhabha Atomic Research Centre Mumbai Maharashtra India
- Department of Chemical Sciences Homi Bhabha National Institute Mumbai Maharashtra India
| |
Collapse
|
5
|
Guleria M, Sharma R, Amirdhanayagam J, Sarma HD, Rangarajan V, Dash A, Das T. Formulation and clinical translation of [ 177Lu]Lu-trastuzumab for radioimmunotheranostics of metastatic breast cancer. RSC Med Chem 2021; 12:263-277. [PMID: 34046615 PMCID: PMC8128050 DOI: 10.1039/d0md00319k] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2020] [Accepted: 10/14/2020] [Indexed: 11/21/2022] Open
Abstract
Trastuzumab (Herceptin®) is an approved immunotherapeutic agent used for the treatment of metastatic breast cancer over-expressing HER2 antigen receptors. The aim of the present work is to standardize the formulation protocol of [177Lu]Lu-trastuzumab addressing various reaction parameters, evaluating the efficacy of the radiolabeled product by in vitro investigations, scaling-up the preparation for administration in patients and performing preliminary clinical studies in patients suffering from metastatic breast cancer. Trastuzumab was conjugated with a suitable bi-functional chelating agent namely, p-NCS-benzyl-DOTA. On average 6.15 ± 0.92 p-NCS-benzyl-DOTA molecules were observed to be attached to each trastuzumab moiety. [177Lu]Lu-trastuzumab could be prepared with >95% radiochemical purity (% RCP) employing the optimized radiolabeling procedure. In vitro studies revealed the affinity of [177Lu]Lu-trastuzumab towards HER2 +ve cancer cell lines as well as against HER2 protein (K d = 13.61 nM and 11.36 nM, respectively). The value for percentage immunoreactive fraction (% IRF) for [177Lu]Lu-trastuzumab was observed to be 76.92 ± 2.80. Bio-distribution studies in Swiss mice revealed non-specific uptake in the blood, liver, lungs and heart followed by gradual clearance of activity predominantly through the hepatobiliary route. Preliminary clinical studies carried out in 8 cancer patients with immunohistochemically proven HER2 positive metastatic breast cancer revealed preferential localization of [177Lu]Lu-trastuzumab in breast cancer lesions, which was in concordance with [18F]FDG-PET scans recorded earlier in the same patient indicating the potential of the agent towards radioimmunotheranostic applications.
Collapse
Affiliation(s)
- Mohini Guleria
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre Trombay Mumbai - 400085 India +91 22 2550 5151 +91 22 2559 0613
| | - Rohit Sharma
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre Trombay Mumbai - 400085 India +91 22 2550 5151 +91 22 2559 0613
| | - Jeyachitra Amirdhanayagam
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre Trombay Mumbai - 400085 India +91 22 2550 5151 +91 22 2559 0613
| | - Haladhar D Sarma
- Radiation Biology and Health Sciences Division, Bhabha Atomic Research Centre Trombay Mumbai - 400085 India
| | - Venkatesh Rangarajan
- Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Hospital Parel Mumbai - 400012 India
| | - Ashutosh Dash
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre Trombay Mumbai - 400085 India +91 22 2550 5151 +91 22 2559 0613
- Homi Bhabha National Institute Anushaktinagar Mumbai - 400094 India
| | - Tapas Das
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre Trombay Mumbai - 400085 India +91 22 2550 5151 +91 22 2559 0613
- Homi Bhabha National Institute Anushaktinagar Mumbai - 400094 India
| |
Collapse
|
6
|
Kumar C, Pareri A, Kambli D, Amirdhanayagam J, Guleria M, Das T, Dash A. Radioimmunotherapy of B-cell lymphoma: In vitro investigations of 177Lu-rituximab on raji cells. J Radiat Cancer Res 2020. [DOI: 10.4103/jrcr.jrcr_28_20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
7
|
Guleria M, Das T, Kumar C, Sharma R, Amirdhanayagam J, Sarma HD, Dash A. Effect of Number of Bifunctional Chelating Agents on the Pharmacokinetics and Immunoreactivity of 177Lu-labeled Rituximab: A Systemic Study. Anticancer Agents Med Chem 2019; 18:146-153. [PMID: 28745238 DOI: 10.2174/1871520617666170725164530] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2017] [Revised: 05/30/2017] [Accepted: 07/19/2017] [Indexed: 11/22/2022]
Abstract
OBJECTIVE Monoclonal antibodies (mAbs) have been radiolabeled with a variety of radioisotopes utilizing various kinds of bi-functional chelating agents (BFCAs) with an aim to develop suitable agents for radioimmunotherapy. The number of BFCA moieties present per antibody molecule plays a significant role in determining the pharmacokinetics and immunoreactivity exhibited by the radiolabeled antibodies. The objective of the present study is to evaluate the effect of the number of BFCA moieties present per antibody molecule on the pharmacokinetics and immunoreactivity of the 177Lu-labeled Rituximab. METHODS Three different mAb-BFCA conjugates were prepared using different molar ratios of Rituximab (mAb) to p-NCS-benzyl-DOTA (BFCA) viz. 1:5, 1:10 and 1:50 employing different reaction conditions. Studies were carried out to determine the average number of BFCAs attached per mAb molecule. All the three mAb-BFCA conjugates were labeled with 177Lu(III) and were subsequently evaluated in normal Swiss mice to ascertain their respective pharmacokinetic behavior. In-vitro studies were also performed in Raji cell lines (human burkitt's lymphoma) for determining the effect of increasing number of BFCAs attached per mAb molecule on the immunoreactivity of the resultant 177Lu-labeled mAb-BFCA complexes. RESULTS 177Lu-labeled mAb-BFCA complex prepared corresponding to 1:50 mAb to BFCA ratio exhibited the least non-specific uptake and rapid clearance from majority of the organs, but also exhibited least immunoreactive fraction (IRF = 19.37%). On the other hand, 177Lu-labeled mAb-BFCA complex prepared corresponding to 1:5 mAb to BFCA ratio exhibited the highest non-specific uptake and slower clearance pattern, but highest IRF (71.17%). 177Lu-labeled mAb-BFCA complex prepared corresponding to 1:10 mAb:BFCA ratio exhibited intermediate pharmacokinetic behaviour with moderate IRF (53.05%). CONCLUSIONS The present study indicates that antibody to BFCA ratio plays a crucial role in determining the immunoreactivity and pharmacokinetic behavior of the radiolabeled antibodies and must be prudently chosen for their successful therapeutic application.
Collapse
Affiliation(s)
- Mohini Guleria
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai-400 085, India
| | - Tapas Das
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai-400 085, India.,Homi Bhabha National Institute, Anushaktinagar, Mumbai-400 094, India
| | - Chandan Kumar
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai-400 085, India
| | - Rohit Sharma
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai-400 085, India
| | | | - Haladhar D Sarma
- Radiation Biology and Health Sciences Division, Bhabha Atomic Research Centre, Trombay, Mumbai-400 085, India
| | - Ashutosh Dash
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai-400 085, India.,Homi Bhabha National Institute, Anushaktinagar, Mumbai-400 094, India
| |
Collapse
|
8
|
Guleria M, Das T, Vats K, Amirdhanayagam J, Mathur A, Sarma HD, Dash A. Preparation and evaluation of 99mTc-labeled porphyrin complexes prepared using PNP and HYNIC cores: studying the effects of core selection on pharmacokinetics and tumor uptake in a mouse model. Medchemcomm 2019; 10:606-615. [PMID: 31057740 DOI: 10.1039/c8md00559a] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/13/2018] [Accepted: 02/16/2019] [Indexed: 11/21/2022]
Abstract
Porphyrins are tetrapyrrolic macrocyclic ligands known for their affinity towards neoplastic tissues and once radiolabeled with a suitable diagnostic radioisotope could potentially be used for the imaging of tumorous lesions. In the present study, an unsymmetrically substituted porphyrin derivative namely 5-(p-amino-propyloxyphenyl)-10,15,20-tris(carboxymethyleneoxyphenyl)-porphyrin was synthesized and modified further to enable radiolabeling with 99mTc using two different 99mTc-cores viz. 99mTc-HYNIC (hydrazino nicotinic acid) and 99mTc(N)PNP2 (PNP2 = bis-[(2-dimethylphosphino)ethyl]-methoxy-ethylamine) in order to study the effect of employing different 99mTc-cores on tumor affinity and pharmacokinetic behavior of the resultant 99mTc-labeled porphyrin complexes. 99mTc-Porphyrin complexes were characterized by reversed phase HPLC studies and could be prepared with >95% radiochemical purity under optimized radiolabeling conditions. Both 99mTc-complexes were found to be adequately stable in human blood serum till 3 h post-preparation. Bio-distribution studies, carried out in Swiss mice bearing fibrosarcoma tumors, revealed relatively higher tumor uptake for the 99mTc-HYNIC-porphyrin complex (3.95 ± 1.42 and 3.28 ± 0.27% IA per g) compared to that exhibited by the 99mTc(N)PNP-DTC-porphyrin complex (1.52 ± 0.53 and 1.56 ± 0.10% IA per g) at 1.5 and 3 h post-administration, although the former complex exhibited comparatively lower lipophilicity in the octanol-water system. Higher uptake and longer retention in the blood were observed for the 99mTc-HYNIC-porphyrin complex (6.63 ± 0.75 and 4.36 ± 0.25% IA per g) compared to that exhibited by the 99mTc(N)PNP-DTC-porphyrin complex (2.41 ± 0.54 and 2.30 ± 0.16% IA per g) at both 1.5 and 3 h post-administration. However, relatively lower liver uptake was observed for the former complex (19.26 ± 3.48 and 18.45 ± 1.05% IA per g) than that exhibited by the latter one (39.37 ± 3.88 and 34.15 ± 8.25% IA per g) at both 1.5 and 3 h post-administration. This study indicates that the in vivo behavior exhibited by the 99mTc-labeled porphyrins not only depends on their lipophilicity/hydrophilicity but is also governed by the Tc-cores employed for radiolabeling.
Collapse
Affiliation(s)
- Mohini Guleria
- Radiopharmaceuticals Division , Bhabha Atomic Research Centre , Trombay , Mumbai - 400085 , India . ; ; Tel: +91 22 2559 0613
| | - Tapas Das
- Radiopharmaceuticals Division , Bhabha Atomic Research Centre , Trombay , Mumbai - 400085 , India . ; ; Tel: +91 22 2559 0613.,Homi Bhabha National Institute , Anushaktinagar , Mumbai - 400094 , India
| | - Kusum Vats
- Radiopharmaceuticals Division , Bhabha Atomic Research Centre , Trombay , Mumbai - 400085 , India . ; ; Tel: +91 22 2559 0613
| | - Jeyachitra Amirdhanayagam
- Radiopharmaceuticals Division , Bhabha Atomic Research Centre , Trombay , Mumbai - 400085 , India . ; ; Tel: +91 22 2559 0613
| | - Anupam Mathur
- Radiopharmaceuticals Program , Board of Radiation and Isotope Technology , Vashi , Navi Mumbai - 400703 , India
| | - Haladhar D Sarma
- Radiation Biology and Health Sciences Division , Bhabha Atomic Research Centre , Trombay , Mumbai - 400085 , India
| | - Ashutosh Dash
- Radiopharmaceuticals Division , Bhabha Atomic Research Centre , Trombay , Mumbai - 400085 , India . ; ; Tel: +91 22 2559 0613.,Homi Bhabha National Institute , Anushaktinagar , Mumbai - 400094 , India
| |
Collapse
|
9
|
Guleria M, Das T, Amirdhanayagam J, Shinto AS, Kamaleshwaran KK, Pandian A, Sarma HD, Dash A. Convenient Formulation of 68Ga-BPAMD Patient Dose Using Lyophilized BPAMD Kit and 68Ga Sourced from Different Commercial Generators for Imaging of Skeletal Metastases. Cancer Biother Radiopharm 2019; 34:67-75. [DOI: 10.1089/cbr.2018.2605] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
Affiliation(s)
- Mohini Guleria
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, India
| | - Tapas Das
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, India
- Homi Bhabha National Institute, Anushaktinagar, Mumbai, India
| | | | - Ajit S. Shinto
- Department of Nuclear Medicine and PET, Kovai Medical Center and Hospital, Coimbatore, India
| | | | - Arun Pandian
- Department of Nuclear Medicine and PET, Kovai Medical Center and Hospital, Coimbatore, India
| | - Haladhar D. Sarma
- Radiation Biology and Health Sciences Division, Bhabha Atomic Research Centre, Mumbai, India
| | - Ashutosh Dash
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, India
- Homi Bhabha National Institute, Anushaktinagar, Mumbai, India
| |
Collapse
|
10
|
Guleria M, Kumar C, Das T, Amirdhanayagam J, Sharma R, Sarma HD, Dash A. Studies towards elucidating the potential of 5,10,15,20-tetrakis( p-carboxy-methyleneoxyphenyl)porphyrin as a theranostic agent for applications in PET and PDT. Medchemcomm 2018; 9:657-666. [PMID: 30108956 DOI: 10.1039/c7md00433h] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/22/2017] [Accepted: 02/06/2018] [Indexed: 12/11/2022]
Abstract
Porphyrins, owing to their inherent tendency to accumulate in tumorous lesions, are considered suitable for developing agents for theranostic applications involving tumor diagnosis and targeted tumor therapy. The aim of the present work is to study the potential of a porphyrin derivative namely, 5,10,15,20-tetrakis(p-carboxymethyleneoxyphenyl)porphyrin (SPTA) as a theranostic agent for applications in positron emission tomography (PET) and photodynamic therapy (PDT). SPTA was synthesized in-house following a three-step reaction process and characterized by using spectroscopic techniques, viz. UV-vis, FT-IR, 1H-NMR and 13C-NMR spectroscopy, as well as by mass spectrometry. SPTA was labeled with 68Ga, a generator produced PET radioisotope, and the radiolabeled product was characterized by HPLC. The 68Ga-SPTA complex was prepared with a radiochemical purity of >95% under optimized conditions. The diagnostic potential of 68Ga-SPTA was evaluated by cell uptake studies in two different tumor cell lines (HT1080 and A549) which revealed the affinity of 68Ga-SPTA towards the cancer cells. Biodistribution studies carried out in Swiss mice bearing fibrosarcoma tumors exhibited the accumulation of the radiotracer in the tumor. The therapeutic potential of SPTA was evaluated by determining its photo-cytotoxicity employing the MTT assay in HT1080 and A549 cell lines using three different light doses, which indicated the significant cytotoxicity of SPTA in the presence of light. The present study indicates the possible potential of SPTA in radionuclide imaging as well as in photodynamic therapy (PDT) thus confirming the promising theranostic nature of this porphyrin derivative.
Collapse
Affiliation(s)
- Mohini Guleria
- Radiopharmaceuticals Division , Bhabha Atomic Research Centre , Trombay , Mumbai - 400085 , India . ; ; Tel: +91 22 2559 0613
| | - Chandan Kumar
- Radiopharmaceuticals Division , Bhabha Atomic Research Centre , Trombay , Mumbai - 400085 , India . ; ; Tel: +91 22 2559 0613
| | - Tapas Das
- Radiopharmaceuticals Division , Bhabha Atomic Research Centre , Trombay , Mumbai - 400085 , India . ; ; Tel: +91 22 2559 0613.,Homi Bhabha National Institute , Anushaktinagar , Mumbai - 400094 , India
| | - Jeyachitra Amirdhanayagam
- Radiopharmaceuticals Division , Bhabha Atomic Research Centre , Trombay , Mumbai - 400085 , India . ; ; Tel: +91 22 2559 0613
| | - Rohit Sharma
- Radiopharmaceuticals Division , Bhabha Atomic Research Centre , Trombay , Mumbai - 400085 , India . ; ; Tel: +91 22 2559 0613
| | - Haladhar D Sarma
- Radiation Biology and Health Sciences Division , Bhabha Atomic Research Centre , Trombay , Mumbai - 400085 , India
| | - Ashutosh Dash
- Radiopharmaceuticals Division , Bhabha Atomic Research Centre , Trombay , Mumbai - 400085 , India . ; ; Tel: +91 22 2559 0613.,Homi Bhabha National Institute , Anushaktinagar , Mumbai - 400094 , India
| |
Collapse
|
11
|
Guleria M, Das T, Amirdhanayagam J, Sarma HD, Dash A. Comparative Evaluation of Using NOTA and DOTA Derivatives as Bifunctional Chelating Agents in the Preparation of 68Ga-Labeled Porphyrin: Impact on Pharmacokinetics and Tumor Uptake in a Mouse Model. Cancer Biother Radiopharm 2018; 33:8-16. [DOI: 10.1089/cbr.2017.2337] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Affiliation(s)
- Mohini Guleria
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, India
| | - Tapas Das
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, India
- Homi Bhabha National Institute, Mumbai, India
| | | | - Haladhar D. Sarma
- Radiation Biology and Health Sciences Division, Bhabha Atomic Research Centre, Mumbai, India
| | - Ashutosh Dash
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, India
- Homi Bhabha National Institute, Mumbai, India
| |
Collapse
|
12
|
Guleria M, Das T, Kumar C, Amirdhanayagam J, Sarma HD, Banerjee S. Preparation of clinical-scale 177
Lu-Rituximab: Optimization of protocols for conjugation, radiolabeling, and freeze-dried kit formulation. J Labelled Comp Radiopharm 2017; 60:234-241. [DOI: 10.1002/jlcr.3493] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2016] [Revised: 01/24/2017] [Accepted: 02/04/2017] [Indexed: 11/07/2022]
Affiliation(s)
- Mohini Guleria
- Radiopharmaceuticals Division; Bhabha Atomic Research Centre; Mumbai India
| | - Tapas Das
- Radiopharmaceuticals Division; Bhabha Atomic Research Centre; Mumbai India
- Homi Bhabha National Institute; Mumbai India
| | - Chandan Kumar
- Radiopharmaceuticals Division; Bhabha Atomic Research Centre; Mumbai India
| | | | - Haladhar D. Sarma
- Radiation Biology and Health Sciences Division; Bhabha Atomic Research Centre; Mumbai India
| | - Sharmila Banerjee
- Homi Bhabha National Institute; Mumbai India
- Radiation Medicine Centre; Bhabha Atomic Research Centre; Mumbai India
| |
Collapse
|